These past few years have marked the acceleration of the adoption of in silico techniques for more efficient and innovative clinical research. When embarking on a new R&D program, scientists face a strategic imperative to assemble the best and most relevant available data and insights.
Jinkō, Novadiscovery’s in silico clinical trial simulation platform, has been designed to build and maintain a high-quality knowledge repository, allowing teams to seamlessly cooperate, both internally and with external thought leaders.
During the first part of this webinar, featured speaker Dr. Friehs, will explain her role and how she uses jinkō with her fellows to extract, classify and qualify pieces of knowledge in a systematic, transparent and traceable manner, and use these in research reports and literature reviews. After that, featured speaker Frédéric (CPO of Novadiscovery) will showcase how this knowledge is then leveraged directly within jinkō to help lower cost and ethical constraints as well as achieve greater trial efficiency through the design and simulation of in silico trials. This will be illustrated with two practical use cases using Nova’s non-small cell lung cancer (NSCLC) disease model of epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma (LUAD). First, by exploring a large range of doses and then by testing eligibility criteria refinement and its impact on treatment effectiveness.
Join this webinar to learn more about using a clinical trial simulation platform to generate auditable and reproducible digital evidence.
Frédéric Cogny, CPO, Novadiscovery
Frédéric Cogny graduated from Ecole Polytechnique in Paris with an Applied Mathematics Master in Probabilities and Finance. He then worked for 12 years in financial market modeling and quantitative trading across London, Tokyo and Singapore. His early focus at Nova was on industrializing the science of biosimulation with systematic model hypothesis testing through the prism of scenarios and large scale simulations.
Now in charge of the jinkō roadmap he ensures the platform development delivers the best product experience and the most value to Nova’s customers and users.Message Presenter
Who Should Attend?
- Biotech & Pharma companies
- Clinicians & scientists
- Patient advocacy groups
- Healthcare providers
What You Will Learn
During this webinar you will learn how jinkō:
- Is rethinking scientific literature review
- Can help refine eligibility criteria for patient eligibility in the next trial
- Is used to design, run and analyze the results of in silico trials
- Is helping generate auditable and reproducible digital evidence for submission dossiers
Nova has built the world’s first collaborative clinical trial simulation platform, jinkō, for pharma companies to bring innovative medicines to patients faster and with greater confidence.